BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the appointment of Tom Polen, 43, as president of BD, effective immediately. In his new role, Mr. Polen will oversee all of BD's operating segments – the Medical and Life Sciences segments, as well as the new Interventional segment, which will include the C. R. Bard, Inc. (NYSE: BCR) businesses following the close of BD's acquisition of Bard, which was also announced today. Mr. Polen, currently executive vice president and president of the BD Medical Segment, will continue to report to Vince Forlenza, who remains chairman and CEO of BD.